Searched for
PHARMA MARKETS
Torrent Pharmaceuticals Q1 Results: Profit rises 3% to Rs 566 croreTorrent Pharmaceuticals announced a robust profit after tax of Rs 566 crore for the first quarter, showcasing impressive growth. Revenue so...- 5 AI award categories that every AI-innovation platform should nominate themselves inArtificial intelligence is transforming industries with independent reasoning and complex workflow orchestration. New AI products are drivi...
- Alembic Pharma gets USFDA approval for generic chronic constipation treatment tabletsAlembic Pharmaceuticals announced USFDA approval for its generic prucalopride tablets. The company received final approval for strengths of...
- Tariff on generic drugs: Loud announcement, little consequence? 7 pharma stocks with upside potential of up to 31%The threat of a US tariff on Indian pharma is no longer a vague fear; or at least that is what President Trump wants us to believe. There i...
- Pharma mutual funds top return charts across horizons. Should investors chase the rally or stay cautious?Pharma mutual funds are leading returns in CY2026, driven by strong earnings, defensive demand, and US export growth. Despite recent outper...
- Looking for better SIP returns? This mutual fund category has outperformedSystematic investment plans build wealth, but returns differ across mutual fund types. Sectoral funds, particularly pharma and healthcare, ...
- US tariff proposal wake-up call for Indian pharma to diversify, innovate: ExpertsUS pharma tariffs: Experts have urged a shift towards global diversification and prioritising innovation for Indian pharma to lessen market...
- With a little help from pharma friends: Psychedelics for psychiatric therapyEli Lilly's acquisition signals a return of psychedelic drugs for mental health. These compounds offer a new approach to rewiring neural co...
- Pharma deal activity hits four-quarter low, but mega Sun Pharma acquisition drives valueIndia's pharma and healthcare sector recorded 65 deals worth $13.9 billion in Q2 CY2026, with volumes falling 17% quarter-on-quarter to a f...
- Cipla in no hurry to launch semaglutide as Yurpeak gains tractionCipla is focusing on its tirzepatide brand Yurpeak in India's obesity market. Yurpeak has become the second largest GLP-1 product since its...
- Trump's 200% generic drug tariff threat puts $9.7 billion Indian pharma exports at risk; industry says reshoring not practicalUS President Trump's proposed tariffs on imported generic drugs will not immediately affect Indian drugmakers. Indian companies export sign...
- Why did market fall today? 7 triggers behind Rs 4 lakh crore wealth wipeoutIndian stock markets experienced significant declines on Wednesday. Escalating Iran-US tensions and tariff threats spooked investors, causi...
- Explained: What Donald Trump's up to 200% pharma tariffs mean for Indian investorsDonald Trump's announcement of tariffs of up to 200% on pharmaceutical imports triggered a selloff in Indian pharma stocks. However, analys...
- Indian pharma firms may yet survive Trump's 200% tariff bombshellDonald Trump's proposed up to 200% tariff on generic drug imports has raised concerns for Indian pharma companies, but industry experts say...
- 200% Trump tariff shock? India’s cheap pills may still beat US rivalsUS President Donald Trump's proposed tariffs of up to 200% on imported generic medicines could put pressure on India's pharmaceutical expor...
- Trump's Generic Drug Tariffs Explained: What it means for Indian pharma before the 200% stormTrump's generic drug tariffs plan provides Indian drugmakers a two-year duty-free window. This allows companies time to reassess manufactur...
- Trump announces new generic drugs tariff plan: No tariffs for 2 years, then 100%, and then 200%For Indian exporters, the two-year tariff-free period offers additional time to reassess supply chains and investment plans. While the imme...
- Sun Pharma, Cipla & other pharma stocks shed over 2% as Trump announces up to 200% tariffs on generic drugs from 2028Pharma stocks, including Sun Pharma, Cipla, Lupin and Dr Reddy's, fell up to 2.5% after US President Donald Trump announced a phased tariff...
- Natco Pharma shares surge 5% after US FDA's tentative nod Olaparib tabletsNatco Pharma shares rose sharply on Monday after the U.S. FDA granted tentative approval for its generic Olaparib tablets, a bioequivalent ...
- Alembic Pharma partner NATCO gets USFDA tentative nod for generic Olaparib tablets; US market size at USD 1.4 bnAlembic Pharmaceuticals and NATCO Pharma received tentative USFDA approval for generic Olaparib tablets. This approval is for a cancer drug...
Load More
